GlassScriptPhysician profile
Devon L Sarvary
NPI 1487297859
$4,413.30
in general payments reported to CMS, 2019-2025
39 companies · $716 in 2025
The $716 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,143 · 2022: $914 · 2023: $808 · 2024: $833 · 2025: $716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,320 · Education: $36.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,320.12 |
| Education | $36.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $466.55 | 2021-2024 | |
| Glaxosmithkline, LLC. | $350.99 | 2021-2023 | Arexvy, Trelegy Ellipta, Shingrix |
| Vanda Pharmaceuticals INC. | $309.42 | 2024-2025 | Fanapt, Hetlioz |
| Lilly USA, LLC | $268.02 | 2021-2024 | Mounjaro, Trulicity, Zepbound |
| Currax Pharmaceuticals LLC | $237.60 | 2022-2025 | Contrave, Nexletol, Nexlizet |
| Amgen INC. | $210.03 | 2021-2025 | Otezla, Repatha, Repatha |
| Neurocrine Biosciences, INC. | $204.37 | 2024-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $200.07 | 2021-2025 | Rexulti, Abilify Asimtufii |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $191.14 | 2021-2024 | Xifaxan |
| Abbvie INC. | $174.10 | 2021-2024 | |
| Esperion Therapeutics, INC. | $161.52 | 2021 | |
| Novartis Pharmaceuticals Corporation | $153.94 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $124.37 | 2021-2024 | Farxiga, Breztri, Airsupra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $119.18 | 2024-2025 | Caplyta |
| Lundbeck LLC | $118.88 | 2024-2025 | Rexulti |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devon Sarvary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.